Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2010, Pages 283-292

  Ronconi, Luca ^a   Aldinucci, Donatella ^b   Dou, Q Ping ^c   Fregona, Dolores ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drug; Dithiocarbamate; Gold compounds; Metallodrug; Nephrotoxicity; Proteasome inhibitor; Reactive oxygen species (ROS); Thioredoxin reductase (TrxR)

Indexed keywords

CISPLATIN; DITHIOCARBAMIC ACID DERIVATIVE; GOLD COMPLEX; GOLD DITHIOCARBAMATE COMPLEX; UNCLASSIFIED DRUG;

ALOPECIA; BONE MARROW SUPPRESSION; CANCER RESEARCH; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW;

EID: 77951660776     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010791162298     Document Type: Review

References (64)

1. Rosenberg, B. Fundamental studies with cisplatin. Cancer, 1985, 55, 2303-2316.
2. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7, 573-584.
3. Sun, R.W.-Y; Ma, D.-L.; Wong, E.L.-M; Che, C.-M. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans., 2007, 4884-4892.
4. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12, 197-206.
5. Kostova, I. Platinum complexes as anticancer agents. Recent Pat. Anti-Cancer Drug Discov., 2006, 1, 1-22.
6. Jakupec, M.A.; Galanski, M.; Arion, V.B.; Hartinger, C.G.; Keppler, B.K. Antitumour metal compounds: more than theme and variations. Dalton Trans., 2008, 183-194.
7. Wang, X.; Guo, Z. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans., 2008, 1521-1532. (Pubitemid 351365759)
8. Kostova, I. Gold coordination complexes as anticancer agents. Anti-Cancer Agents Med. Chem., 2006, 6, 19-32. (Pubitemid 43803127)
9. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
10. Tiekink, E.R.T. Anti-cancer potential of gold complexes. Inflammopharmacology, 2008, 16, 138-142.
11. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Chem. Res., 2010, DOI: 10.1002/med.20168.
12. Johnson, N.P.; Butour, J.L.; Villani, G.; Wimmer, F.L.; Defais, M.; Pierson, V.; Brabec, V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med., 1989, 10, 1-24.
13. Aldinucci, D.; Ronconi, L.; Fregona, D. Groundbreaking gold(III) anticancer agents. Drug Discov. Today, 2009, 14, 1075-1076.
14. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int., 2008, 73, 994-1007. (Pubitemid 351543900)
15. Wang, X; Guo, Z. The role of sulfur in platinum anticancer chemotherapy. Anti-Cancer Agents Med. Chem., 2007, 7, 19-34. (Pubitemid 46062403)
16. Dorr, R.T. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2, Pinedo, H.M and Schornagel, J.H., Eds.; Plenum Press: New York, 1996; pp. 131-154.
17. Borch, R.F.; Dedon, P.C.; Gringeri, A.; Montine, T.J. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Nicolini, M., Ed.; Martinus Nijoff Publishing: Boston, 1988; pp. 216-281.
18. Segovia, N.; Crovetto, G.; Lardelli, P.; Espigares, M. In vitro toxicity of several dithiocarbamates and structure-activity relationships. J. Appl. Toxicol., 2002, 22, 353-357. (Pubitemid 35378853)
19. Marzano, C.; Bettio, F.; Baccichetti, F.; Trevisan, A.; Giovagnini, L.; Fregona, D. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem.-Biol. Interact., 2004, 148, 37-48. (Pubitemid 38824659)
20. Osswald, H.; Frank, N. Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210. J. Cancer Res. Clin. Oncol., 1990, 116, 448-452.
21. Ronconi, L.; Maccato, C.; Barreca, D.; Saini, R.; Zancato, M.; Fregona, D. Gold(III) dithiocarbamate derivatives of N-methylglycine: an experimental and theoretical investigation. Polyhedron, 2005, 24, 521-531. (Pubitemid 40269966)
22. Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.; Fregona, D. Synthesis, characterization and comparative in vitro cytotoxicity studies of platinum(II), palladium(II) and gold(III) methylsarcosinedithiocarbamate complexes. J. Med. Chem., 2005, i, 1588-1595.
23. Aldinucci, D.; Lorenzon, D.; Stefani, L.; Giovagnini, L.; Colombatti, A.; Fregona, D. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Anti-Cancer Drugs, 2007, 18, 323-332.
24. Aldinucci, D.; Cattaruzza, L.; Lorenzon, D.; Giovagnini, L.; Fregona, D.; Colombatti, A. Antiproliferative and apoptotic effects of two new Pd(II) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Oncol. Res., 2008, 17, 103-113.
25. Eastman, A. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Lippert, B., Ed. Wiley-VCH: Weinheim, 1999; pp. 111-134.
26. Ronconi, L.; Giovagnini, L.; Marzano, C.; Bettio, F.; Graziani, R.; Pilloni, G.; Fregona, D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties and in vitro antitumor activity. Inorg. Chem., 2005, 44, 1867-1881.
27. Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Maccà, C.; Trevisan, A.; Fregona, D. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J. Med. Chem., 2006, 49, 1648-1657.
28. Arnesano, F.; Natile, G. Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coord. Chem. Rev., 2009, 253, 2070-2081.
29. Koelle, U.; Laguna, A. Electrochemistry of Au-complexes. Inorg. Chim. Acta, 1999, 290, 44-50.
30. Marzano, C.; Baccichetti, F.; Trevisan, A.; Giovagnini, L.; Fregona, D. Cytotoxicity and DNA damage induced by a new Pt(II) complex with pyridine and dithiocarbamate. Chem.-Biol. Interact., 2002, 140, 215-219.
31. Minko, I.G.; Zou, Y.; Lloyd, R.S. Incision of DNA-protein crosslinks by UvrABC nuclease suggests a potential repair pathway involving nucleotide excision repair. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 1905-1909.
32. Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253, 1692-1707.
33. Saggioro, D.; Rigobello, M.P.; Paloschi, L.; Folda, A.; Moggach, S.A.; Parsons, S.; Ronconi, L.; Fregona, D.; Bindoli, A. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol., 2007, 14, 1128-1139.
34. Lincoln, D.T.; Ali Emadi, E.M.; Tonissen, K.F.; Clarke, F.M. The thioredoxin-thioredoxin reductase system: overexpression in human cancer. Anticancer Res., 2003, 23, 2425-2434.
35. Sun, Y.; Rigas, B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res., 2008, 68, 8269-8277.
36. Singh, S.S.; Li, Y.; Ford III, O.H.; Wrzosek, C.S.; Mehedint, D.C.; Titus, M.A.; Mohler, J.L. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Transl. Oncol., 2008, 1, 153-157.
37. Yamada, M.; Tomida, A.; Yoshikawa, H.; Taketani, Y.; Tsuruo, T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res., 1996, 2, 427-432.
38. Kim, S.J.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Nakamura, H.; Yodoi, J.; Kato, K.; Noguchi, S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res., 2005, 11, 8425-8430.
39. Powis, G.; Kirkpatrick, D.L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol., 2007, 7, 392-397.
40. Cattaruzza, L.; Fregona, D.; Mongiat, M.; Ronconi, L.; Fassina, A.; Colombatti, A.; Aldinucci, D. Antitumor activity of gold(III)- dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer, DOI: 10.1002/ijc.25311.
41. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics. CA Cancer J. Clin., 2009, 59, 225-229.
42. Brunelle, J.K.; Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell. Sci., 2009, 122, 437-441.
43. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 2009, 15, 1126-1132.
44. Bonaccorsi, L.; Marchiani, S.; Muratori, M.; Forti, G.; Baldi, E. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J. Cancer Res. Clin. Oncol., 2004, 130, 604-614.
45. Di Lorenzo, G.; Tortora, G.; D'Armiento, F.P.; De Rosa, G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De Placido, S.; Catalano, G.; Bianco, A.R.; Ciardiello, F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res., 2002, 8, 3438-3444.
46. Schlomm, T.; Kirstein, P.; Iwers, L. Daniel, B.; Steuber, T.; Walz, J.; Chun, F.H.K.; Haese, A.; Kollermann, J.; Graefen, M.; Huland, H.; Sauter, G.; Simon, R.; Erbersdobler, A. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin. Cancer Res., 2007, 13, 6579-6584.
47. Bratland, A.; Boender, P.J.; Høifødt, H.K. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin. Exp. Metastasis, 2009, 26, 485-496.
48. Milacic, V.; Fregona, D.; Dou, Q.P. Gold complexes as prospective metal-based anticancer drugs. Histol. Histopathol., 2008, 23, 101-108.
49. Milacic, V.; Dou, Q.P. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord. Chem. Rev., 2009, 253, 1649-1660.
50. Milacic, V.; Chen, D.; Ronconi, L.; Landis-Piwowar, K.R.; Fregona, D.; Dou, Q.P. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res., 2006, 66, 10478-10486.
51. Lopes, U.G.; Erhard, P.; Yao, R.; Cooper, G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 1997, 272, 12893-12896.
52. Wang, Y.; He, Q.Y.; Sun, R.W.; Che, C.M.; Chiu, J.F. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res., 2005, 65, 11553-11564.
53. Szweda, P.A.; Friguet, B.; Szweda, L.I. Proteolysis, free radicals, and aging. Free Radic. Biol. Med., 2002, 33, 29-36.
54. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y.; Bi, C.; Fregona, D.; Dou, Q.P. Inhibition of tumor proteasome activity by gold dithiocarbamato complexes via both redox-dependent and - independent processes. J. Cell. Biochem., 2010, 109, 162-172.
55. Perez-Galan, P.; Roue, G.; Villamar, N.; Montserrat, E.; Campo, E.; Colomer, D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.
56. Fregona, D.; Ronconi, L.; Marzano, C. Complessi ditiocarbammici di oro(III) e loro impiego come antitumorali. It. Patent 0001347835, October 02, 2008.
57. Cristofori, P.; Zanetti, E.; Fregona, D.; Piaia, A.; Trevisan, A. Renal proximal tubule segment-specific nephrotoxicity: an overview on biomarkers and histopathology. Toxicol. Pathol., 2007, 35, 270-275.
58. Oncotest GmbH. http://www.oncotest.de/drug-screening/index.php (Accessed January 15, 2010).
59. Casini, A.; Kelter, G.; Gabbiani, C. Cinellu, M.A.; Minghetti, G.; Fregona, D.; Fiebig, H.H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 2009, 14, 1139-1149.
60. Salmaso, S.; Sermenzato, A.; Bersani, S.; Matricardi, P.; Rossi, F.; Caliceti, P. Cyclodextrin/PEG based hydrogels for multi-drug delivery. Int. J. Pharm., 2007, 345, 42-50.
61. Guryanov, I.; Tarasenko, I.; Pankova, G.; Vlasov, G.; Gorbunova, S.; Vorobjev, V.; Ronconi, L.; Giovagnini, L.; Fregona, D. Lysine dendrimers and starburst copolymers as new carriers of anticancer drugs based on the complexes of platinum and gold. J. Pept. Sci., 2008, 14(Suppl. S), 160.
62. Biegel, A.; Gebauera, S.; Hartrodta, B.; Knütter, I.; Neuberta, K.; Brondschb, M.; Thondorf, I. Recognition of 2-aminothiazole-4-acetic acid derivatives by the peptide transporters PEPT1 and PEPT2. Eur. J. Pharm. Sci., 2007, 32, 69-76.
63. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci., 2002, 23, 434-440.
64. Ronconi, L.; Formaggio, F.; Aldinucci, A.; Dou, Q.P.; Fregona, D. Gold(III) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents. PCT Int. Appl. 053296, March 20, 2009.